An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:
Ghany MG; Nelson DR; Strader DB; Thomas DL; Seeff LB and 1 more

Journal:
Hepatology

Publication Year: 2011

DOI:
10.1002/hep.24641

PMCID:
PMC3229841

PMID:
21898493

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Hepatology

Abbreviation: Hepatology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A global action agenda for turning the tide on fatty liver disease.
Lazarus JV; Mark HE; Allen AM and 44 more (2023) - Transparency Score: 3/6
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.
Leslie J; Hunter JE; Collins A and 15 more (2023) - Transparency Score: 3/6
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex wi…
Mizushima D; Takano M; Aoki T and 7 more (2023) - Transparency Score: 3/6
Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hep…
Gömer A; Klöhn M; Jagst M and 12 more (2023) - Transparency Score: 3/6
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
Juárez-Fernández M; Goikoetxea-Usandizaga N; Goikoetxea-Usandizaga N and 18 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Potential conflict of interest: Dr. Nelson receives research support from Vertex, Merck, Phamassett, Genentech/Roche, Gilead, Bristol-Myers Squibb, Tibotec, Bayer/Onyx and serves on advisory boards of Merck, Pharmassett, Genentech/Roche, Gilead, Tibotec, and Bayer/Onyx, and is a consultant for Vertex."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025